Male HRT for Health & Longevity - Quick Reference Sheet
evipedia.ai ← Back

Male HRT for Health & Longevity

Created on 06/19/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 – Audit

Restores testosterone to youthful levels via injection, skin gel, or pellet. Strongest evidence supports gains in muscle, libido, and bone strength; more moderate help for body fat, mood, and blood sugar. Reliably thickens the blood and suppresses fertility. Decades-long effects relevant to longevity remain unknown. (Full Review)

Protocol

Confirm Deficiency
Two morning fasting draws
Low total testosterone plus hormonal/safety panel and reversible-cause workup before starting
Formulation
Injection, gel, or pellet
Cypionate/enanthate ~75–100 mg weekly; gel ~50–100 mg daily; long-acting undecanoate or pellets
Dosing Style
Start low, titrate to mid-normal
Smaller, more frequent subcutaneous injections keep levels stable and minimize peaks
Time to effect
Muscle & Body Composition
3–12 months
Builds over months, especially with resistance training
Libido & Mood
3–6 weeks
Often the earliest noticeable changes
Bone Density
A year or more
Continues to improve over a year or more

Benefits

Contraindications
  • Known or suspected prostate cancer or male breast cancer
  • Very high baseline hematocrit (e.g., >54%)
  • Actively trying to conceive (without fertility-sparing measures)
  • Untreated severe obstructive sleep apnea
  • Recent cardiovascular events (e.g., myocardial infarction or stroke within ~3–6 months)
  • Severe untreated heart failure (e.g., NYHA Class III–IV)
  • Recent or active venous clot (deep vein thrombosis or pulmonary embolism)
    •
Key Interactions
  • Anticoagulants and antiplatelet drugs (warfarin, apixaban, clopidogrel)
  • Corticosteroids and other fluid-retaining drugs (prednisone, NSAIDs such as ibuprofen)
  • Insulin and oral diabetes medications (metformin, sulfonylureas)
  • Over-the-counter supplements that raise hematocrit or clotting tendency (iron)
  • Supplements with additive androgenic or hormonal effects (DHEA, pro-hormones, testosterone boosters)
  • Supplements affecting estrogen conversion (zinc, botanicals)
  • 5-alpha-reductase inhibitors (finasteride, dutasteride)
    •

Risk & Side Effects

  • High: Erythrocytosis (excess red blood cells); suppressed fertility and testicular atrophy
    •
  • Medium: Cardiovascular and thromboembolic events; worsening of sleep apnea; acne and oily skin
    •
  • Low: Accelerated male-pattern hair loss; gynecomastia and estrogen-related effects; prostate effects (benign growth and rising PSA)
    •
  • Speculative: Long-term dependence on exogenous hormone; unknown very-long-term cardiovascular and cancer outcomes
    •

Monitoring

Marker Target Why
Total testosterone ~500–800 ng/dL Confirms deficiency at baseline and that therapy restores youthful-physiologic levels
Free testosterone ~16–31 pg/mL The biologically active fraction; reflects true androgen exposure better than total alone
SHBG ~20–45 nmol/L Determines how much testosterone is free and active
Estradiol (E2) ~20–40 pg/mL Tracks aromatization; too high causes gynecomastia, too low harms bone, libido, lipids
Hematocrit <50% (action threshold ~54%) Detects erythrocytosis, the key dose-limiting safety marker
PSA (prostate-specific antigen) <1.5–2.5 ng/mL, stable Prostate safety surveillance
LH / FSH Suppressed on therapy (expected) Confirms HPG-axis suppression; informs fertility and restart decisions
Lipid panel LDL <100 mg/dL, HDL >40 mg/dL Monitors cardiometabolic effect; testosterone can modestly lower HDL
HbA1c / fasting glucose HbA1c <5.4%; glucose 70–90 mg/dL Tracks metabolic benefit, especially in men with insulin resistance

Cadence: Follow-up panel at ~6–8 weeks, again at 3 and 6 months, then every 6–12 months once stable; PSA and prostate exam at baseline, 3–6 months, then annually in age-appropriate men.

Qualitative Assessment

  • Libido and sexual function: improvement in sexual desire is often the earliest and most reliable subjective marker of adequate restoration
  • Energy and fatigue: sustained improvement in daytime energy and reduced fatigue, interpreted cautiously given large placebo effects
  • Mood and motivation: reduced low mood and improved sense of drive and wellbeing
  • Strength and body composition: noticeable gains in strength, muscle, and reduced abdominal fat over months, especially with training
  • Sleep quality: tracked both as a benefit and as a safety signal for emerging or worsening sleep apnea
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.